ClinicalTrials.Veeva

Menu

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Pneumococcal Vaccines

Treatments

Biological: 13vPnC

Study type

Interventional

Funder types

Industry

Identifiers

NCT00824655
6096A1-3012

Details and patient eligibility

About

The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar. The study will also assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine at 5 and 12 months or 12 months of age. In addition, reactions at the injection site will be assessed during the study.

Enrollment

234 patients

Sex

All

Ages

140 to 392 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy children previously immunized with 1 or 2 doses of Prevenar.
  • Group 1: Male or female subjects between the age of >=140 and <=196 days of age at time of enrollment.
  • Group 2: Male or female subjects between the age of >=336 and <=392 days of age at time of enrollment
  • Available for entire study period.

Exclusion criteria

  • Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component.
  • Previous vaccination with licensed or investigational pneumococcal vaccine other than Prevenar.

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

234 participants in 2 patient groups

Group 1
Experimental group
Treatment:
Biological: 13vPnC
Biological: 13vPnC
Group 2
Experimental group
Treatment:
Biological: 13vPnC
Biological: 13vPnC

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems